Vulva Cancer

The EORTC vulva cancer module is developed as a disease- and treatment specific questionnaire module for vulva cancer patients to supplement the EORTC QLQ-C30. The aim of the study is to test the scale structure, reliability, and validity of the EORTC VU34 in patients diagnosed with vulva cancer at different stages of disease and with different treatment modalities.We aim to develop a questionnaire module that allow broad international cross-cultural and cross-country adaptation which can be used in clinical trials.

The three first phases of development and validation is completed. The questionnaire is now undergoing formal field testing with psychometric analyses.

Current status:
Phase 4, currently recruiting.

The phase 3 paper needs editing and acceptance by collaborators and EC in the EORTC. Expected to be published June/July 2023
Two centers outside Europe (Jordan and Isreal) have been recruited as collaborators. Translations are finalized for Jordan. Awaiting final approval for the Hebraic Planned to start inclusion within short time.

The EORTC vulva cancer module is a specific questionnaire for patients with vulva cancer. We aim to test the validity of the questionnaire for use in patients from different countries, at different disease stages and in patients  undergoing different treatments. This will allow us to use the disease-specific questionnaire in the clinic and in future studies.This will allow us to use the questionnaire in the clinic and in future studies.